Comparative Pharmacology
Head-to-head clinical analysis: EDECRIN versus ETHACRYNIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDECRIN versus ETHACRYNIC ACID.
EDECRIN vs ETHACRYNIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethacrynic acid inhibits the Na-K-Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to diuresis.
Inhibits sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, potassium, and water. Also inhibits prostaglandin degradation.
Oral: 50-100 mg once or twice daily, maximum 400 mg/day. IV: 50 mg (0.5 mg/kg) once, may repeat once at 2-hour intervals if needed.
50 to 100 mg orally once daily; may increase by 25 to 50 mg increments at intervals of 2 to 3 days up to 400 mg/day. IV: 0.5 to 1 mg/kg slowly (over several minutes); usual initial dose 50 mg.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours; prolonged in renal impairment (up to 30 hours) and in heart failure.
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Approximately 60-70% excreted unchanged in urine via glomerular filtration and tubular secretion; remaining 30-40% eliminated via biliary/fecal route.
Primarily renal (approximately 60-70% as unchanged drug and metabolites) with some biliary/fecal excretion (approximately 30-40%).
Category C
Category C
Loop Diuretic
Loop Diuretic